Park Hotels & Resorts Inc. (NYSE:PK ) Q4 2024 Earnings Conference Call February 20, 2025 11:00 AM ET Company Participants Ian Weissman - SVP, Corporate Strategy Tom Baltimore - Chairman & CEO Sean Dell'Orto - CFO Conference Call Participants Floris Van Dijkum - Compass Point Duane Pfennigwerth - Evercore ISI David Katz - Jefferies Smedes Rose - Citibank Chris Woronka - Deutsche Bank Chris Darling - Green Street Patrick Scholes - Truist Securities Jay Kornreich - Wedbush Securities Robin Farley - UBS Dori Kesten - Wells Fargo David Hargreaves - Barclays Aryeh Klein - BMO Capital Markets Operator Greetings and welcome to the Park Hotels and Resorts Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
The headline numbers for Park Hotels & Resorts (PK) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Park Hotels & Resorts (PK) came out with quarterly funds from operations (FFO) of $0.39 per share, missing the Zacks Consensus Estimate of $0.40 per share. This compares to FFO of $0.52 per share a year ago.
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –
Park Hotels & Resorts gets a neutral hold rating today, in line with the Seeking Alpha quant system. While undervalued, other factors paint a mixed picture to consider. Key strengths are a dividend yield above 10%, a strong profit margin and cash flow, macro-level demand growth for hotel travel, and a portfolio diversified across the US. Some weaknesses are a credit rating below investment-grade by S&P, a high debt/equity vs peers, lack of proven dividend growth, and the potential recessionary nature of the tourism sector overall.
NEW YORK and MELBOURNE, Australia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced positive topline results from a completed pharmacokinetics (PK) and safety study of IHL-42X, a novel, oral fixed-dose combination of acetazolamide and dronabinol for the treatment of Obstructive Sleep Apnea (OSA).
TYSONS, Va.--(BUSINESS WIRE)---- $PK #dividends--Park Hotels & Resorts Inc. (NYSE:PK) (“Park” or the “Company”) today announced the tax reporting information for its 2024 cash distributions on its Common Stock. The distributions, totaling $1.40 per share, were paid as follows: $0.25 on April 15, 2024; $0.25 on July 15, 2024; $0.25 on October 15, 2024; and $0.65 on January 15, 2025. For income tax purposes, the dividends for 2024, totaling $1.40 per share, are classified as: (i) $1.285731 (91.8379%) Total ordi.
Park Hotels & Resorts Inc. offers a 10% dividend yield and a 24% discount to Q3's book value per share. Management currently guides for portfolio adjustments from non-core assets into core assets and buybacks, suggesting capital flexibility. The full-year dividend in 2024 appears to be lower for that reason.
TYSONS, Va.--(BUSINESS WIRE)---- $PK #earnings--Park Hotels & Resorts Inc. (NYSE: PK) (“Park”) today announced that it plans to report financial results for the fourth quarter and full year 2024 after the stock market closes on Wednesday, February 19, 2025. Park will hold a conference call on Thursday, February 20, 2025, at 11:00 a.m. Eastern Time (ET) to discuss its earnings results and outlook for 2025. The conference call will be accessible by telephone and through the internet. Interested individuals are.
PK provides preliminary fourth-quarter 2024 operating trends, along with capital allocations.